Genomics and biotech firm 23andMe is set to launch a free genetics test that lets people know their likelihood of developing type 2 diabetes. Users input personal metrics, including the number of times they exercise or eat fast food per week, and receive a percentage figure representing their chances of developing the disease. They can also find out how lifestyle changes can lower that percentage. The company has developed several genetic tests in years, including for Alzheimer's and Parkinson's. It also became the first firm to receive Food and Drug Administration approval for a direct-to-consumer risk test for cancer.
Genomics and biotech firm 23andMe is set to launch a free genetics test that lets people know their likelihood of developing type 2 diabetes. Users input personal metrics, including the number of times they exercise or eat fast food per week, and receive a percentage figure representing their chances of developing the disease. They can also find out how lifestyle changes can lower that percentage. The company has developed several genetic tests in recent years, including for Alzheimer's and Parkinson's. It also became the first firm to receive Food and Drug Administration approval for a direct-to-consumer risk test for cancer.